These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 24590902

  • 1. New method to predict DCIS recurrence.
    Printz C.
    Cancer; 2013 Nov 15; 119(22):3899. PubMed ID: 24590902
    [No Abstract] [Full Text] [Related]

  • 2. Treatment of ductal carcinoma in situ.
    Mokbel K, Wells C, Carpenter R.
    N Engl J Med; 1999 Sep 23; 341(13):998-9; author reply 1000. PubMed ID: 10498500
    [No Abstract] [Full Text] [Related]

  • 3. Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins?
    Chan LW, Rabban J, Hwang ES, Bevan A, Alvarado M, Ewing C, Esserman L, Fowble B.
    Int J Radiat Oncol Biol Phys; 2011 May 01; 80(1):25-30. PubMed ID: 20646871
    [Abstract] [Full Text] [Related]

  • 4. Predicting residual disease and local recurrence in patients with ductal carcinoma in situ.
    Silverstein MJ.
    J Natl Cancer Inst; 1997 Sep 17; 89(18):1330-1. PubMed ID: 9308697
    [No Abstract] [Full Text] [Related]

  • 5. [Carcinoma in situ. Prognostic factors].
    Trojani M.
    Arch Anat Cytol Pathol; 1994 Sep 17; 42(5):234-50. PubMed ID: 7872815
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of loss heterozygosity in primary and recurrent ductal carcinoma in situ of the breast.
    Lininger RA, Fujii H, Man YG, Gabrielson E, Tavassoli FA.
    Mod Pathol; 1998 Dec 17; 11(12):1151-9. PubMed ID: 9872644
    [Abstract] [Full Text] [Related]

  • 7. Treatment of ductal carcinoma in situ.
    Harries SA, Johnston AO, Parker SJ.
    N Engl J Med; 1999 Sep 23; 341(13):999; author reply 1000. PubMed ID: 10498501
    [No Abstract] [Full Text] [Related]

  • 8. Do sentinel node micrometastases predict recurrence risk in ductal carcinoma in situ and ductal carcinoma in situ with microinvasion?
    Murphy CD, Jones JL, Javid SH, Michaelson JS, Nolan ME, Lipsitz SR, Specht MC, Lesnikoski BA, Hughes KS, Gadd MA, Smith BL.
    Am J Surg; 2008 Oct 23; 196(4):566-8. PubMed ID: 18760400
    [Abstract] [Full Text] [Related]

  • 9. Treatment of ductal carcinoma in situ.
    Heimann R, Karrison T, Hellman S.
    N Engl J Med; 1999 Sep 23; 341(13):999-1000. PubMed ID: 10498502
    [No Abstract] [Full Text] [Related]

  • 10. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Arun B, Sneige N, Pusztai L, Buchholz TA, Sahin A, Hunt KK, Meric-Bernstam F, Ross MI, Ames FC, Kuerer HM.
    Cancer; 2006 Jan 01; 106(1):42-50. PubMed ID: 16333852
    [Abstract] [Full Text] [Related]

  • 11. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis.
    Boyages J, Delaney G, Taylor R.
    Cancer; 1999 Feb 01; 85(3):616-28. PubMed ID: 10091735
    [Abstract] [Full Text] [Related]

  • 12. Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience.
    Padmore RF, Fowble B, Hoffman J, Rosser C, Hanlon A, Patchefsky AS.
    Cancer; 2000 Mar 15; 88(6):1403-9. PubMed ID: 10717623
    [Abstract] [Full Text] [Related]

  • 13. Duct carcinoma in situ: biological implications for clinical practice.
    Lagios MD.
    Semin Oncol; 1996 Feb 15; 23(1 Suppl 2):6-11. PubMed ID: 8614847
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Breast-conserving therapy in young women with invasive carcinoma of the breast.
    Borg MF.
    Australas Radiol; 2004 Sep 15; 48(3):376-82. PubMed ID: 15344990
    [Abstract] [Full Text] [Related]

  • 17. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
    Poller DN, Silverstein MJ, Galea M, Locker AP, Elston CW, Blamey RW, Ellis IO.
    Mod Pathol; 1994 Feb 15; 7(2):257-62. PubMed ID: 7911998
    [Abstract] [Full Text] [Related]

  • 18. Extensive apoptosis in ductal carcinoma in situ of the breast.
    Bodis S, Siziopikou KP, Schnitt SJ, Harris JR, Fisher DE.
    Cancer; 1996 May 01; 77(9):1831-5. PubMed ID: 8646681
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Histological margin and residual disease assessment for breast carcinoma].
    Sigal-Zafrani B, Fourquet A, Vincent-Salomon A, Fréneaux P, Génin P, Rosty C, Sastre-Garau X.
    Cancer Radiother; 2003 Nov 01; 7 Suppl 1():120s-123s. PubMed ID: 15124553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.